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The efﬁcacy of high-dose chemotherapy (HDC) and autologous hemopoietic progenitor cell transplantation
(AHPCT) for breast cancer (BC) patients has been an area of intense controversy among the medical oncology
community. The aim of this study was to assess toxicity and efﬁcacy of this procedure in a large cohort of high-
risk primary BC patients who underwent AHPCT in Italy. A total of 1183 patients receiving HDC for high-risk BC
(HRBC) (>3 positive nodes) were identiﬁed in the Italian registry. The median agewas 46 years, 62% of patients
were premenopausal at treatment, 60.1% had endocrine-responsive tumors, and 20.7% had a human epidermal
growth factor receptor 2 (HER2)epositive tumor. The median number of positive lymph nodes (LN) at surgery
was 15, with 71.5% of patients having 10 positive nodes. Seventy-three percent received an alkylating agent-
based HDC as a single procedure, whereas 27% received epirubicin or mitoxantrone-containing HDC, usually
within a multitransplantation program. The source of stem cells was peripheral blood in the vast majority of
patients. Transplantation-related mortality was .8%, whereas late cardiac and secondary tumor-related mor-
tality were around 1%, overall. With amedian follow-up of 79months, median disease-free and overall survival
(OS) in the entire population were 101 and 134 months, respectively. Subgroup analysis demonstrated that OS
was signiﬁcantly better in patients with endocrine-responsive tumors and in patients receiving multiple
transplantation procedures. HER2 status did not affect survival probability. The size of the primary tumor and
number of involved LN negatively affected OS. Adjuvant HDCwith AHPCT has a lowmortality rate and providesdgments on page 505.
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P. Pedrazzoli et al. / Biol Blood Marrow Transplant 20 (2014) 501e506502impressive long-term survival rates in patients with high-risk primary BC. Our results suggest that this treat-
ment modality should be proposed in selected HRBC patients and further investigated in clinical trials.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION nodes, pN2) between 1990 and 2005. The primary outcome were DFS andTable 1
Patient Demographic and Clinical Characteristics
Characteristic n %
No. of patients 1183 100.0
Age, median (range), yr 46 (28-66)
Menopausal status
Premenopausal 734 (62.0) 62.0
Postmenopausal 449 (38.0) 38.0
Missing information 0 0
ER/PR status
Negative 290 (24.5) 24.5
Positive 711 (60.1) 60.1
Missing information 182 (15.4) 15.4
HER2 status
Negative 324 (27.4) 27.4
Positive 245 (20.7) 20.7
Missing information 614 (51.9) 51.9
Positive lymph nodes, median (range) 15 (4-63)
4-9 337 (28.5) 28.5
10-19 568 (48.0) 48.0
20 278 (23.5) 23.5
Tumor size, cm
5 875 (74.0) 74.0
>5 308 (26.0) 26.0
HER2 indicates human epidermal growth factor receptor 2; ER, estrogen
receptor; PR, progesterone receptor.
Data shown are n (%) unless otherwise indicated.The clinical correlation between chemotherapy (CT) dose
intensity, achieved either by increasing the single dose per
cycle (ie, higher dose) or by reducing the intervals between
cycles (ie, dose density), and outcome in breast cancer (BC)
has been described since the 1980s [1,2]. This led, along with
phase II studies apparently demonstrating signiﬁcant favor-
able outcomes compared with historical data, to the pre-
mature acceptance of high-dose chemotherapy (HDC) with
autologous hematopoietic progenitor cell transplantation
(AHPCT) as a treatment option both in the adjuvant and
metastatic settings, with up to nearly 2000 patients per year
undergoing this procedure in the mid-1990s in Europe [3].
Unfortunately, the vast majority of patients were treated
outside of prospective randomized studies.
At the turn of the century, in view of early reports of ran-
domized trials not showing a signiﬁcant overall survival (OS)
beneﬁt of HDC [4], the vastmajority ofmedical oncologists no
longer considered this procedure an option. In the era of great
expectations for targeted drugs, data from randomized
studies demonstrating an OS beneﬁt of HDC for high-risk
breast cancer (HRBC) [5,6], along with additional evidence
of thebeneﬁt of intensiﬁedCT, didnot change this attitude [7].
Recently, Berry et al. published the ﬁrst meta-analysis
using individual data from 15 trials for patients with HRBC,
showing a signiﬁcant beneﬁt of HDCwith AHPCT for disease-
free survival (DFS) but not for OS [8]. The authors conclude
that HDC with autologous support for patients with BC, as it
was studied in these trials, does not produce sufﬁcient
beneﬁt to be “worthwhile,” despite an apparent improve-
ment of OS conﬁned to women with human epidermal
growth factor receptor 2 (HER2)enegative disease, which is
biologically plausible and supported by clinical data [6,9,10].
Based on the data of subgroup analyses and on the
perspective of the new oncology aiming for individualized
therapeutic strategies, some authors suggested that the
clear-cut view of the meta-analysis is questionable, as HDC
might be of potential beneﬁt in selected patients, considering
the present limited toxicity of the procedure [11-14].
As a contribution to this ﬁeld, we report the results of this
approach in a large cohort of patients treated in Italy be-
tween 1990 and 2005.
METHODS
The “Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali
emopoietiche e terapia cellulari” (GITMO) is an association established in
1987 with the purpose of designing and coordinating studies and collecting
data from national and international (mainly via collaboration with the
European Group for Blood andMarrow Transplantation) clinical research on
patients undergoing autologous and allogeneic transplantation in Italy.
GITMO centers, which are homogenously distributed through the country,
are required to send patient data to the central European Group for Blood
and Marrow Transplantation database on a yearly basis, either directly or
through the GITMO itself. There are 2 levels of data: minimal essential data
type A, which are compulsory and consider major items, such as de-
mographic data, disease classiﬁcation, type of transplantation, outcomes,
and follow-up; and minimal essential data type B, referring to items sent on
a volunteer basis (type of conditioning or mobilization regimens, compli-
cations, number of cells transplanted, etc).
Study Design and End Points
The purpose of the present study was to analyze the registry data on
AHPCT performed in the adjuvant setting of HRBC (3 or more involvedOS; secondary end points were transplantation-related mortality (TRM),
nonrelapse mortality (NRM), and identiﬁcation of clinical and biologic fea-
tures that may inﬂuence outcome of HDC. DFS and OS rates were measured
from the date of transplantation to the date of last follow-up or death and
the date of relapse, respectively. TRM was deﬁned as mortality from any
cause other than disease progression within 100 days of transplantation.
NRM was deﬁned as mortality from any cause other than disease progres-
sion and TRM after the transplantation.
Before starting the present analysis, GITMO centers were contacted for
missing data.
Statistics
Probabilities of DFS, OS, and TRM were calculated using the Kaplan-
Meier product limit estimate. The log-rank test was used for comparisons
of DFS and survival between groups; stratifying parameters included
menopausal status, age, hormone receptor status (estrogen- or
progesterone-receptor positive versus both negative), HER2 status (positive
versus negative), number of positive lymph nodes (LN), primary tumor (T)
categories, and multiple versus single HDC.
RESULTS
Among 1352 patients reported in the registry, 1183 were
available for OS analysis and represent the body of this paper.
One hundred sixty-nine were excluded for incomplete data,
erroneous reporting (ie, evidence of metastatic disease), or
having <4 positive LN at surgery. The baseline patient and
treatment characteristics are summarized in Table 1 and
Table 2, respectively. The median age was 46 years (range, 28
to 66), and 62% of the women were premenopausal. Data on
hormone receptor (HR) status and HER2 status were avail-
able in 1001 patients (85%) and 569 patients (48%), respec-
tively. Triple negative (TN) disease was documented in 85
patients. Twenty six percent of patients had breast masses
larger than 5 cm; the median lymph node involvement at
surgery was 15 (range, 4 to 63); the number of patients
having 4 to 9, 10 to 19, and  20 pathologic nodes was 337
(28.5%), 568 (48%), and 278 (23.5%), respectively.
Table 2
Treatment Characteristics
Characteristics of the treatments Value
No. of cycles of conventional chemotherapy before
AHPCT, median (range)
3 (0-6)
Containing anthracyclines 90
Containing taxanes/anthracyclines 33
Time from breast cancer diagnosis to transplantation,
median (range), wk
14 (3-25)
Peripheral blood CD34þ cells >95
Single AHPCT 80.1
Multi AHPCT 19.9
Conditioning treatment
High-dose alkylating agents* 73
With adriamycin/epirubicin or mithoxantrone 27
Hormonal therapy after AHPCT 63
AHPCT indicates autologous hemopoietic progenitor cell transplantation.
Data are shown percentage (%) unless otherwise indicated.
* Either thiothepa or melphalan in 90% of cases.
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peripheral blood HPC (>95%) and all patients received
granulocyte colony-stimulating factor support after trans-
plantation; 236 patients (19.9%) underwent the procedure
more than once. The conditioning regimens included alky-
lating agents in 73% of cases, either thiothepa or melphalan
(90%), and adriamycin/epirubicin or mitoxantrone were used
in 27% of cases. In a few cases of T4 disease and Nþ clinical
involvement, a single high-dose procedure after conventional
dose CT was performed before surgery as neoadjuvant ther-
apy. Conventional anthracycline-based or, in more recent
years, anthracycline/taxane-based adjuvant chemotherapy
always preceded HDC, but only in the triple AHPCT setting
[15]. Among patients with HR-positive tumors, the vast ma-
jority were treated with tamoxifen after HDC. Radiotherapy
was administered after completion of CT, accordingwith local
recommendations.Disease-free and Overall Survival Estimates
Kaplan-Meier curves of DFS and OS for the whole study
population are shown in Figure 1A and B, respectively. With a
median follow-up of 7.1 years, the DFS was 9.6 years, with
65% of patients free of disease at 5 years, whereas median OS
was not reached, with 75% of the patients alive 5 years after
transplantation.
Menopausal status (Figure 2A) and age < 50 versus 
50 years did not affect survival. We found that survival was
statistically better for patients with HR-positive and smaller
(T1 to T2) tumors (Figure 2B and C). In our series, HER2 status
did not affect survival. TN patients performed well with
AHPCT (medianOS,110months or 9.2 yrs), althoughoutcome,
as expected,wasworse comparedwith thewhole population.Figure 1. Kaplan-Meier curves of (A) disease-free survival anPatients with 4 to 9 positive axillary nodes had 85% sur-
vival probability at 5 years; this result decreasing approxi-
mately by 10% for patients with 10 to 19 positive nodes and
by a further 10% for patients with 20 or more positive nodes
(Figure 2D).
Patientswho underwentmultiple HDC had a superior DFS
and OS (Figure 3A) compared with single HDC, not reaching
the median yet in both parameters, with 75% of them still
alive and disease free 7.5 years after transplantation. This
favorable effect was more clearly observed in patients with
>9 positive LN (Figure 3B).
Toxicity and Secondary Malignancies
Because of the limited information provided by the
minimal essential data type A form, detailed information on
acute and long-term morbidity, including grade of mucositis
and occurrence of infection, cannot be provided.
Treatment-induced menopause, deﬁned as >2 years of
amenorrhea after HDC with no resumption of menses, was
found in a large proportion of patients who were premeno-
pausal at the time of diagnosis.
Neutrophil and platelet recovery occurred in all but 4
patients who died before engraftment for infections. Overall
TRM occurred in 9 of 1183 (.8%); NRM was negligible (16 of
1183, 1.4%) and this consisted of heart failure (2 of 1183, 0.2%)
or second neoplasia (14 of 1183, 1.2%). Most second malig-
nancies were gynecologic and there was a single case of
acute leukemia.
DISCUSSION
The present study, reporting a retrospective analysis of
data on HDC and AHPCT for HRBC in Italy, includes 1 of the
largest series (1183 patients) in this setting. Despite that, we
are aware of its limitations inherent to the retrospective
study design, which selects patients on the basis of patho-
logic staging and those who have successfully achieved both
surgery and HDC with AHPCT, and it excludes those that do
not. Also, nonstandard pretreatment staging might have
been used in some centers.
The patient population subject of the present analysis was
selected to have at least 4 positive LN. Selection based on
axillary node involvement was adopted by all phase III
studies of HDC [8], as it was considered (and it is still today) a
major negative prognostic factor for recurrence. In our study,
patients with more than 10 pathologic nodes were the ma-
jority, and almost one quarter of our patients had more than
20 positive LN. Other patient characteristics, such as age and
premenopausal state, were in line with previous studies
[5,15-19]. Based on these considerations, the present popu-
lation has clinical features and risk of BC recurrence andd (B) overall survival for the whole study population.
Figure 2. Kaplan-Meier estimates of overall survival in prespeciﬁed subset analyses. Subsets by (A) menopausal status, (B) tumor hormone-receptor status, (C) tumor
size, and (D) number of positive lymph nodes. Survival is calculated in months from time of transplantation.
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previous series. Unfortunately, data regarding patterns of
recurrence and salvage therapy were not available, which
represents a limitation of our study.
The data presented here revealed a very low toxicity of
this approach, in terms of TRM, with death rates that are
comparable with those of conventional CT. This is particu-
larly signiﬁcant considering that 20% of patients underwent
multiple cycles of HDC. The introduction of myeloid growth
factors after transplantation, the use of blood in place of bone
marrow stem cells, and other improvements in supportive
care reduced the TRM rate from the initial unacceptable 4% to
10% rate [20,21] to the current <1% expected in experienced
transplantation units [22,23]. Thus, HDC has become sub-
stantially less toxic over time and today it should be
considered a safe procedure [3,5] with a mortality rate and
quality-adjusted survival parameters [24], similar to
conventional CT. In addition, HDC regimens associatedwith a
high TRM, ie, the cyclophosphamide/BCNU/cisplatin regimen
[20], are no longer utilized and were only anecdotally used in
our series.Figure 3. Kaplan-Meier estimates of overall survival. Comparison of multiple versu
cedures. (A) Shows the whole study population. (B) Shows patients with  10 positiLong-term toxicity was also not relevant. Gynecologic
malignancies were prevalent among second tumors and
might well be related to the presence of germline mutations
of BRCA genes (ovarian cancer) or the use of adjuvant
tamoxifen (uterine cancer). Heart failure was merely occa-
sional, as was secondary acute leukemia, which occurred
only in 1 case.
The survival beneﬁt from HDC, which in our series appear
to match favorably with previous adjuvant studies in similar
patient population [25,26], was observed independently of
age and menopausal state. No interference of the meno-
pausal state was observed, possibly because a higher pro-
portion of premenopausal women at the time of HDC
became persistently amenorrheic after the procedure [5].
The impact of prognostic factors for survival, such as HR
positivity, was maintained. Positivity for HR is a known
positive prognostic factor, characterized usually by more
indolent disease, and allows for hormonal targeted therapy
after recovery from HDC, an opportunity that may have
further inﬂuenced these results. Improved outcomes for HR-
positive versus HR-negative disease is a recurrent feature ins single high-dose chemotherapy (HDC) and autologous transplantation pro-
ve lymph nodes.
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pointed out that women with HR-positive disease had the
most evident beneﬁt from HDC [15]. HER2 status did not
affect DFS and OS in our series, in contrast with previous
reports [11]. This is likely to be related to the fact that 48.1%
of patients had HER2 status available, so the analysis was
conducted in a limited portion of our patients. The study by
Rodenhuis et al. [6] underscored a difference in terms of DFS
and OS in favor of the HER2-negative population, and dis-
cussed this ﬁnding in terms of insufﬁcient anthracycline
exposure for patients harboring HER2-positive tumors (a
population likely to beneﬁt most from full-dose anthracy-
clines). The vast majority of HDC regimens used in their
study did not include anthracycline in the conditioning
regimen. One can hypothesize that the different results re-
ported in our studies may be related to the signiﬁcant
number of HDC regimens containing anthracyclines (27%),
and/or the introduction of anti-HER2 drugs in the adjuvant
or metastatic phase.
Unfortunately, TN disease was documented in only 85
patients, so the apparent good results obtained this popula-
tion are insufﬁcient to generate any hypothesis. However,
Gluz et al. [27] found that thebeneﬁt ofHDCwasmoreevident
in a basal-like phenotype (ER and PR receptor negative,
HER2-negative and basal cytokeratin positive) and in grade 3
tumors. Berry’s meta-analysis [8] added to the body of
evidence supporting a possible survival advantage for dose-
intensiﬁcation regimens for TN tumors. Other authors have
speculated that these patients are the most likely to receive a
beneﬁt from HDC [28].
As with other treatment modalities, TN status had an
impact on the HDC outcome, both in DFS and OS, which
underscores the quality of the GITMO data. Highly signiﬁcant
differences in OS are noted if patients are stratiﬁed into 3
groups: 4 to 9, 10 to 19, and more than 20 positive nodes. In
the Rodenhuis study [16], including patients with >3 posi-
tive nodes, the most relevant effect of HDC compared with
conventional CT was observed in terms of DFS in the group
having more than 9 positive LN.
An interesting trend emerging from our study was the
impact of multiple, less intensive, cycles of HDC versus single,
more intense HDC. Overall, the dose intensity might be supe-
rior in the multiple transplantation approach, thus justifying
the better outcome observed in our study and suggested by
previous studies [11]. The strategy consisting of rapidly cycled
HDC courses could be considered mainly for theoretical rea-
sons and clinical trials. On the basis of kinetic models, some
authors discussed early intensiﬁcation strategies to avoid
gradual expansion of clinically not apparent pre-existing sub-
clones of cells that are resistant to the induction regimen and
are hidden by the simultaneous regression of numerically
dominant sensitive clones [29]. As a matter of fact, the best
results of HDC in HRBC were obtained by the German study,
including a double-HDC approach, which was compared with
an appropriate dose-dense conventional CT [5]. A such “high
doseedensity” strategy may increase the intensity of anti-
cancer therapy beyond that achievable with conventional,
dense-dose, or with single HDC [5,6,15,19,30,31]. Cost savings
associated with outpatient-based AHPCT, feasible in BC pa-
tients undergoing less intensive HDC regimens, are also rele-
vant [32,33].
In conclusion, our study, along with some more recent
phase III studies [5,6] and, to some extent, the results from
meta-analysis [8,11], suggest a role for HDC and AHPCT in the
context of HRBC, especially in view of the fact that thisprocedure can now be given safely and with the needed dose
intensiﬁcation, with both early and late minimal toxicity. In
the adjuvant setting of HRBC, HDC with AHSCT may still
represent a therapeutic option that can be proposed to well-
informed patients harboring HER2-negative tumors and
having gross involvement of axillary nodes. In recent years,
new biologic factors have been reported to identify patients
with high-risk primary BC who could beneﬁt from modern
dose-intensiﬁcation regimens [10], and further studies
should be conducted comparing conventional CT with high-
dose strategies in the setting of HRBC, including locally
advanced and inﬂammatory disease.
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